LIMK-IN-1
Based on 1 Customer Validation
LIMK-IN-1 (Compound 14) is an inhibitor of LIM-Kinase (LIMK), with IC50s of 0.5 nM and 0.9 nM for LIMK1 and LIMK2, respectively. LIMK-IN-1 can be used for ocular hypertension and associated glaucoma research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.33%
- No. CAS: 1116571-01-7
- Fòrmula: C20H21BrN8
- Peso molecular:453.34
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-18305
BMS-5LIMK1/2 Inhibitor -
HY-18304
BMS-3LIMK Inhibitor -
HY-120025
CRT0105950LIMK Inhibitor -
HY-122630
TH-257LIMK1/2 Inhibitor -
HY-12659
LX7101LIM/ROCK/PKA Inhibitor -
HY-10071
Y-27632ROCK Inhibitor -
HY-10583
Y-27632 dihydrochlorideROCK Inhibitor -
HY-10583G
Y-27632 dihydrochloride (GMP)ROCK Inhibitor -
HY-19352
T56-LIMKiLIMK Inhibitor -
HY-10583R
Y-27632 dihydrochloride (Standard)ROCK Inhibitor -
HY-11000
GSK429286AROCK Inhibitor -
HY-120097
R-10015LIMK Inhibitor
Actividad biológica
Descripciòn
IC50 & Target
[1]|
LIMK1 0.9 nM (IC50) |
LIMK2 0.5 nM (IC50) |
ROCK1 260 nM (IC50) |
ROCK2 2700 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
0.9 nM
Compound: 14
|
Inhibition of human recombinant LIMK2 expressed in baculovirus-Sf9 system by scintillation counting
Inhibition of human recombinant LIMK2 expressed in baculovirus-Sf9 system by scintillation counting
|
[PMID: 19831390] |
In Vitro
LIMK-IN-1 (Compound 14) (100 nM) increases outflow facility by about 30% in a pig eye perfusion assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
No. CAS 1116571-01-7
-
Appearance Solid
-
Peso molecular 453.34
-
Fòrmula C20H21BrN8
-
Color White to off-white
-
SMILES
CC1=CNC2=NC=NC(N3C[C@H](C)N(/C(NC4=CC=CC(Br)=C4)=N\C#N)CC3)=C21
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvente y solubilidad
In Vitro:
DMSO : 125 mg/mL (275.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocolo
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2058 mL | 11.0292 mL | 22.0585 mL | 55.1462 mL |
| 5 mM | 0.4412 mL | 2.2058 mL | 4.4117 mL | 11.0292 mL | |
| 10 mM | 0.2206 mL | 1.1029 mL | 2.2058 mL | 5.5146 mL | |
| 15 mM | 0.1471 mL | 0.7353 mL | 1.4706 mL | 3.6764 mL | |
| 20 mM | 0.1103 mL | 0.5515 mL | 1.1029 mL | 2.7573 mL | |
| 25 mM | 0.0882 mL | 0.4412 mL | 0.8823 mL | 2.2058 mL | |
| 30 mM | 0.0735 mL | 0.3676 mL | 0.7353 mL | 1.8382 mL | |
| 40 mM | 0.0551 mL | 0.2757 mL | 0.5515 mL | 1.3787 mL | |
| 50 mM | 0.0441 mL | 0.2206 mL | 0.4412 mL | 1.1029 mL | |
| 60 mM | 0.0368 mL | 0.1838 mL | 0.3676 mL | 0.9191 mL | |
| 80 mM | 0.0276 mL | 0.1379 mL | 0.2757 mL | 0.6893 mL | |
| 100 mM | 0.0221 mL | 0.1103 mL | 0.2206 mL | 0.5515 mL |
LIMK-IN-1 Related Classifications
HY-14227 Related Classifications
Powered by Bioz